Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Corgenix Reports Net Sales Of $8.1 Million In Fiscal 2009
Total operating expenses decreased $107,869 or 2.2% vs. the prior year. Operating loss for the fiscal year was $349,490 vs. an operating loss of$602,279 for the prior year.
Total operating expenses decreased $107,869 or 2.2% vs. the prior year. Operating loss for the fiscal year was $349,490 vs. an operating loss of$602,279 for the prior year.
Repligen has announced the publication of research that identifies histone deacetylase 3 (HDAC 3) as an enzyme target for therapeutic intervention in Friedreich’s ataxia. Reportedly, the research findings
Centocor Ortho Biotech has announced that the FDA has approved Stelara (ustekinumab) for the treatment of adult patients 18 years or older with moderate to severe plaque psoriasis
Novartis has received a positive opinion recommending EU approval of QAB149 for maintenance bronchodilator treatment in adult patients with chronic obstructive pulmonary disease (COPD). The company said that
Boston Scientific has declared a two-year follow-up data from the HORIZONS-AMI trial. The trial, sponsored by the Cardiovascular Research Foundation (CRF) with grant support from Boston Scientific and
Icagen has initiated the proof-of-concept study for ICA-105665 in patients with photosensitive epilepsy. ICA-105665 is a novel, orally available opener of subtypes of KCNQ channels, which have been
Pfizer Oncology will initiate a global, phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced
Vical has presented encouraging results from animal studies of a peptide-based cancer vaccine formulated with the Vaxfectin adjuvant. The study demonstrates the adjuvant’s ability to enhance immune responses
Morphotek has reported preliminary data from a phase II trial evaluating the safety and efficacy of farletuzumab in platinum-sensitive epithelial ovarian cancer subjects experiencing their first relapse. Farletuzumab
DOR BioPharma has entered into common stock purchase agreements with institutional investors totaling approximately $3.85m. DOR’s North American commercial partner, Sigma-Tau Pharmaceuticals, participated in this financing. Under the